Phase III Acute Coronary Syndrome

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Acute Coronary Syndrome

In brief

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome

Key facts

Study ID
NCT00831441
Run by
Bristol-Myers Squibb
People needed
7484
Starts
2009-03-01
Expected to finish
2011-03-01
Last updated by the study team
2016-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.